Cidofovir

Concomitant administration is contraindicated due to nephrotoxic potential. Must be discontinued at least 7 days prior to cidofovir therapy.

Concomitant administration is contraindicated due to nephrotoxic potential. Must be discontinued at least 7 days prior to cidofovir therapy.

Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of cidofovir injection infusion. Nephrotoxic Agents Concomitant administration of cidofovir injection and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and nonsteroidal anti-inflammatory agents] is contraindicated. Such agents must be discontinued at least 7 days prior to starting therapy with cidofovir injection.

Concomitant administration is contraindicated due to nephrotoxic potential. Must be discontinued at least 7 days prior to cidofovir therapy.

Concomitant administration is contraindicated due to nephrotoxic potential. Must be discontinued at least 7 days prior to cidofovir therapy.

Intravenous pentamidine concomitant administration is contraindicated due to nephrotoxic potential. Must be discontinued at least 7 days prior to cidofovir therapy.

Nephrotoxic agents Concomitant administration of cidofovir injection and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and nonsteroidal anti-inflammatory agents] is contraindicated.

Nephrotoxic agents Concomitant administration of cidofovir injection and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and nonsteroidal anti-inflammatory agents] is contraindicated.

Probenecid may interfere with cidofovir metabolism or renal excretion. Concomitant medications should be carefully assessed.

Zidovudine should be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of cidofovir infusion.

Eliminated by active tubular secretion; coadministration may increase tenofovir and cidofovir concentrations, increasing adverse reaction risk.

Coadministration may increase concentrations of cidofovir and renally eliminated drugs, increasing risk of adverse reactions.

Monitor patients for increased toxicity when MRP2 inhibitors (e.g., abacavir, adefovir, cidofovir, furosemide, lamivudine, nevirapine, ritonavir, probenecid, saquinavir, and tenofovir) are co-administered with COMETRIQ [see Clinical Pharmacology ( 12.3 )] .

Eliminated by active tubular secretion; may increase concentrations of cidofovir and/or emtricitabine/tenofovir.

Coadministration may increase concentrations of tenofovir and/or cidofovir due to competition for active tubular secretion in the kidneys.

Cidofovir is eliminated by active tubular secretion; coadministration may increase concentrations of cidofovir and emtricitabine/tenofovir, increasing risk of adverse reactions.

Coadministration may increase concentrations of FTC, tenofovir, and cidofovir due to competition for active tubular secretion.

Coadministration may increase concentrations of cidofovir and/or tenofovir due to competition for renal tubular secretion. Monitor for tenofovir toxicity.

Coadministration may increase serum concentrations of emtricitabine, tenofovir, and/or cidofovir due to competition for renal tubular secretion.

Coadministration may increase serum concentrations of FTC, tenofovir, and/or cidofovir due to competition for active tubular secretion.

Coadministration may increase concentrations of FTC, tenofovir, and/or cidofovir due to competition for active tubular secretion in kidneys.

May increase serum tenofovir concentrations and/or increase concentrations of other renally eliminated drugs.

Coadministration may increase tenofovir concentrations due to active tubular secretion competition. Monitor for evidence of tenofovir toxicity.

Drug Interactions Probenecid Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).

Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.6) ] .

Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.3) and Clinical Pharmacology (12.3) ] .

Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ] .

Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.5) ] .

Drug Interactions Probenecid Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).